트라스투주맙 치료에 반응을 보인 HER2/neu 양성 전이성 타액관 암종 1예

• 영문명: Trastuzumab in a Patient with Metastatic Salivary Duct Carcinoma : A Case Report
• 발행기관: 대한두경부종양학회
• 저자명: 공봉한(Bong Han Kong) 이지은(Jieun Lee) 최상수(Sang-Su Choi) 박진희(Jinhee Park) 김연실(Yeon Shil Kim) 김민식(Min-Sik Kim) 이연수(Youn-Soo Lee):이지연(Ji-Yeon Lee):홍숙희(Sook Hee Hong) 강진형(Jin Hyoung Kang)
• 간행물 정보: 『대한두경부종양학회지』제30권 제2호, 90~94쪽, 전체 4쪽
• 주제분류: 의약학 > 종양학
• 파일형태: PDF
• 발행일자: 2014.11.30

영문 초록

Salivary duct carcinoma(SDC) is rare malignancy, accounting for approximately 1-3% of all malignant sali-vary gland tumors. Systemic chemotherapy has been used for stage IV SDC, but there is no consensus on the stan-dard treatment. SDC is histologically similar to ductal carcinoma of breast and often overexpress HER2/neu, hence HER2/neu targeted therapy could be one of treatment options. A 75-year-old Arabian man was diagnosed as SDC of right parotid gland with extensive metastases. He received oral 5-FU as palliative chemotherapy, but he was intolerable to oral chemotherapy due to severe oral mucositis. Considering immunohistochemical stain of tu-mor tissue showing strong positive for HER2/neu, we decided to administer an anti-HER2/neu antibody, trastu-zumab. Follow-up CT scans before the third dose of trastuzumab demonstrated remarkable regression of multiple metastases as well as primary tumor. This case suggests that HER2/neu targeted therapy may be a potential thera-peutic option for the SDC patient with overexpression of HER2/neu.

목차

서 론

증 례

고 찰

결 론

키워드

Salivary duct carcinoma HER2/neu Trastuzumab 타액관 암 HER2/neu 트라스투주맙.